Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25779334 | 0.90 | KDM4E (0.48) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL25779341 | 0.88 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL25779352 | 0.87 | KDM4E (0.44) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL25779307 | 0.80 | LMNA (0.40) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL21070696 | 0.76 | TSHR (0.67) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL26465754 | 0.76 | CYP3A4 (0.33) | LMNA | |
| SCHEMBL13656324 | 0.75 | TSHR (0.58) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL17744972 | 0.74 | TSHR (0.62) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL26465757 | 0.74 | MEN1 (0.48) | USP2ALDH1A1LMNATSHREPHX2 | |
| SCHEMBL6049577 | 0.74 | TSHR (0.58) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139745-A1 | NON-PEPTIDIC POLYMERIC LINKER COMPOUND, CONJUGATE COMPRISING SAME LINKER COMPOUND, AND METHODS FOR PREPARING SAME LINKER COMPOUND AND CONJUGATE | HANMI PHARM. CO., LTD. (KR) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139745-A1 | NON-PEPTIDIC POLYMERIC LINKER COMPOUND, CONJUGATE COMPRISING SAME LINKER COMPOUND, AND METHODS FOR PREPARING SAME LINKER COMPOUND AND CONJUGATE | FCGR1A, FCGR3B, FCGR2A | KDM4E 3512/4885USP2 1841/4885ALDH1A1 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.